Global Impression News Today

Preliminary Safety Results from the Ph1/2 Study of NGN-401, a Novel Regulated Gene Therapy for Rett Syndrome Suter B1, Lieberman D2, Benke T3,...

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is...

Sonelokimab is a novel humanized nanobody that selectively binds to interleukin (IL)-17A and IL-17F.

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 –

Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease is sufficiently powered to continue as planned without any...

By Adam L. Cataldo Annovis Bio's shares gained after the company said an independent statistical group concluded that its Phase 2/3 study could continue as...

Shares of Annovis Bio, Inc. (ANVS) are up 16% on Thursday after the company shared positive news about its Alzheimer's study. ANVS is trading on the New York Stock Exchange at $9.

NEW YORK--(BUSINESS WIRE)--Sep 19, 2023--

Another study showed vaginal estrogen during prolapse repair did not affect surgical outcomes